Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia

Zhang, Y.; Wang, Y.; Zhang, P.; Zhang, X.D.; Yang, Young-Min

doi:10.1016/j.jomh.2009.08.011

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, although immunosuppressants have been greatly improved in the enhancing performance and reducing side effects, the resulting physical and (or) mental uncomfortable symptoms of the recipients would be inevitable. QOL of the patients was mainly affected by their subjective experiences including discomfort or pathological change, which has been verified previously [19,20].…”

Section: Relationships Between the Symptom Occurrence And Symptom Dissupporting

confidence: 77%

Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life

Wei¹

2017

AJCEM

View full text Add to dashboard Cite

Abstract:Influences of the side effects and interferences of immunosuppressants on the quality of life (QOL) of renal transplant recipients have been discussed. 72 renal transplant recipients were surveyed utilizing 25-item health status questionnaires, and modified transplant symptom occurrence and symptom distress scales. The results showed that the frequencies and symptom interferences of side effect after receiving immunosuppressants were below medium level. Physical and mental health related QOL was most significantly affected by symptom occurrence and symptom distress, respectively. Besides, postoperative comorbidity, work status, age and household income have also been demonstrated to be able to predict the postoperative QOL. Side effects all occurred to various extents after receiving immunosuppressants to the renal transplant recipients, the occurrence and interference of the symptoms were not apparent, which would affect the postoperative QOL.

show abstract

Section: Relationships Between the Symptom Occurrence And Symptom Dissupporting

confidence: 77%

Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life

Wei¹

2017

AJCEM

View full text Add to dashboard Cite

show abstract

“…In fact, the previous reports revealed that pharmacological treatments effectively relieve LUT symptoms and are safe for renal graft function. These treatments can improve the QOL of patients with RTX [26,27].…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Lower Urinary Tract Dysfunction and Symptoms After Successful Renal Transplantation

et al. 2015

View full text Add to dashboard Cite

Background:We investigated risk factors for lower urinary tract (LUT) dysfunction and LUT symptoms in patients who successfully underwent renal transplantation (RTX). Material/Methods:Ninety-five patients (54 males and 41 females) undergoing RTX (median age: 45 years old) at Hokkaido University Hospital were included in this study. Uroflowmetry (UFM), postvoid residual urine volume (PVR), and 24-h bladder diaries were performed. We analyzed risk factors for voiding dysfunction, urinary frequency, polyuria, nocturia, and nocturnal polyuria after RTX using logistic regression analysis. Results:End-stage renal disease arose from diabetes mellitus in 18 patients (19%). Pre-transplant dialysis had been carried out in 74 patients. Voiding dysfunction as assessed by UFM and PVR was observed in 24 patients (27%).Based on the 24-h bladder diaries, we identified frequent micturition in 29 patients (35%), polyuria in 44 (54%), nocturia in 30 (37%), and nocturnal polyuria in 46 (56%). A multivariable logistic regression analysis revealed that diabetes mellitus, which may cause autonomic disorders, was a risk factor for voiding dysfunction and nocturnal polyuria. A risk factor for frequent micturition and nocturia was older age at RTX. Being female was a risk factor for polyuria, which suggested that fluid intake in relation to body weight was higher in females. Conclusions:LUT dysfunction and LUT symptoms were not uncommon in patients who successfully underwent RTX. LUT dysfunction and LUT symptoms need to be considered in patients with risk factors such as diabetes mellitus, older age at RTX, and being female, even after successful RTX.

show abstract

“…Doxazosin, a commonly used α1-blocker, is an effective therapeutic agent for improving LUTS and urinary flow rate in men with BPH. Moreover, doxazosin treatment is reported to be safe for patients with an underlying renal insufficient risk [17,18]. In the present study, we Urol Int 2022;106:97-102 DOI: 10.1159/000517534 found that the rate of patients with voiding difficulty in the doxazosin group was only 13% on post-biopsy day 7, which was significantly lower than that in the control group.…”

Section: Discussionmentioning

confidence: 42%

Analysis of Voiding Impairment after Prostate Biopsy and the Effect of Doxazosin Treatment: Outcomes from a Regional Cancer Center

Zheng¹,

Bai²,

Zhang³

et al. 2021

Urol Int

View full text Add to dashboard Cite

Introduction: The aim of this study was to investigate the association of transrectal ultrasound (TRUS)-guided prostate biopsy with voiding impairment and the efficacy of doxazosin treatment. Methods: A prospective observational study including 200 male patients undergoing TRUS-guided prostate biopsy was performed between May 2020 and December 2020. One hundred patients underwent biopsy with doxazosin (doxazosin group). The remaining 100 patients underwent biopsy without doxazosin (control group). All patients were questioned regarding post-biopsy voiding difficulty and acute urinary retention. The International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), and residual urine volume were recorded before biopsy and at 7 and 30 days after biopsy. Results: There were no significant differences in baseline parameters between the two groups. The rate of post-biopsy voiding difficulty in the doxazosin group was significantly lower than that in the control group. Compared with baseline values, doxazosin treatment significantly improved IPSS, quality of life scores, and Qmax after biopsy (p < 0.05). The baseline values of IPSS and prostate size may be risk factors for post-biopsy voiding difficulty. Conclusion: TRUS-guided prostate biopsy causes transient voiding impairments, which may be improved by doxazosin treatment.

show abstract

Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia

Cited by 4 publications

References 0 publications

Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life

Side Effects of Immunosuppressive Regimens After Renal Transplantation and Multiple-Sample Assessment of Quality of Life

Risk Factors for Lower Urinary Tract Dysfunction and Symptoms After Successful Renal Transplantation

Analysis of Voiding Impairment after Prostate Biopsy and the Effect of Doxazosin Treatment: Outcomes from a Regional Cancer Center

Contact Info

Product

Resources

About